Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone

Publisher Website
Google Scholar
Abstract
SUMMARYWe performed a cost-effectiveness analysis to assess the cost-effectiveness of oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA), compared with 5-FU/FA alone to achieve an additional progression-free month or year from the UK NHS perspective. Clinical data from a Phase III clinical trial were used to determine efficacy, in terms of progression-free survival. The average drug-acquisition cost for each cycle of treatment was then calculated. Any toxicities that resulted in hospitalisation of the patient were determined, and the costs incurred were calculated depending on the type of ward to which the patient was admitted. The costs for oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone gave the incremental cost to achieve the improvement in progression-free survival. Sensitivity analyses were performed on costs and progression-free survival to give a range of possible values when costs and outcome were varied. The results of the analysis indicate that the co...

This publication has 10 references indexed in Scilit: